

Friday 24th March 2023

0830-0845	Opening of the Conference		
0845-1015	<p>Plenary 1: Prevent, diagnose and support Chairs: Mark Smithers, Brisbane & H. Peter Soyer, Brisbane</p> <p>Evolution of melanoma diagnosis - Harald Kittler, Vienna (Austria) Building research capacity towards early detection of melanoma - Monika Janda, Brisbane Improving skin cancer management with artificial intelligence - Victoria Mar, Melbourne Panel Discussion - Harald Kittler, Monika Janda, Victoria Mar</p> <p>State of the nation report and the consumer – Victoria Beedle, Gold Coast Consumer Panel: Karen van Gorp, Adelaide Rae Flude, Brisbane Tamara Dawson, Melbourne</p>		
1015-1045	Morning Break		
1045-1215	<p>Session 1.1: Melanoma: burden, control, policy Chairs: David Whiteman, Brisbane & Anne Cust, Sydney</p> <p>Trends in melanoma incidence in Australia - Catherine Olsen, Brisbane</p> <p>The economic burden of melanoma and keratinocytic skin cancer in Australia - Louisa Gordon, Brisbane</p> <p>Skin checks in general practice: The upfront and downstream patterns and costs - David Goldsbury, Sydney</p> <p>Does methotrexate increase melanoma risk? - Mabel Yan, Melbourne</p> <p>Balancing the risks and benefits of sun exposure: recognising the diversity of Australia’s population Sun exposure guideline update - Rachel Neale, Brisbane</p> <p>Panel discussion</p>	<p>Session 1.2: Diagnosis melanoma, what now? Chairs: Sydney Ch’ng</p> <p>Diagnostic biopsy impact on definitive treatment - Pathologist’s view - Louise Jackett, Melbourne</p> <p>- Surgeon’s view - Gerard Bayley, Brisbane</p> <p>- Panel discussion - Louise Jackett, Gerard Bayley</p> <p>Treatment of primary “dermal” melanoma - Robyn Saw, Sydney</p> <p>Treatment of primary desmoplastic melanoma – Ajay Chauhan, Brisbane</p> <p>Quality performance indicators in Melanoma - Richard Martin, Auckland (New Zealand)</p> <p>Panel discussion</p>	<p>Session 1.3: Basic science 1: genetics/genomics Chairs: Mitchell Stark, Brisbane & Felicity Newell, Brisbane</p> <p>The genomics of acral and mucosal melanomas - Felicity Newell, Brisbane</p> <p>Mike Eccles, Dunedin (New Zealand)</p> <p>On the role of aneuploidy in primary cutaneous melanoma - Ismael Vergara, Sydney</p> <p>Mitchell Stark, Brisbane</p> <p>Free papers</p>
1215-1330	<p>Lunch Break</p> <p>Industry Session: Where in the world does Nivolumab+Relatlimab fit? Personalised treatment decisions in first line metastatic melanoma Victoria Atkinson, Brisbane</p>		

	Matteo Carlino, Sydney Rachel Roberts-Thomson, Adelaide <i>Sponsored by Bristol-Myers Squibb Australia</i>		
1330-1500	<p>Session 2.1: Overdiagnosis: population perspectives, potential solutions Chairs: Rachel Neale, Brisbane & Erin McMeniman</p> <p>Overdiagnosis in melanoma: What are the epidemiology studies telling us? - David Whiteman, Brisbane</p> <p>Do we need to rethink the diagnoses melanoma in-situ and severely dysplastic naevus? A review of evidence - Katy Bell, Sydney</p> <p>Diagnostic drift - does it exist and what can we do about it? - Blake O'Brien, Brisbane</p> <p>Building evidence for a targeted national screening program for melanoma - Anne Cust, Sydney</p> <p>Panel discussion</p>	<p>Session 2.2: Surgery and regional treatment Chairs: Robyn Saw, Sydney & Trent Cross</p> <p>The pathologist role in sentinel node biopsy - Robert Rawson, Sydney</p> <p>The radiologist role in sentinel node biopsy - Kevin London, Sydney</p> <p>The surgeon: performing the sentinel node biopsy - Richard Martin, Auckland (NZ)</p> <p>Head and Neck sentinel node biopsy - Sam Yang, Brisbane</p> <p>Discussion - Richard Scolyer, Kevin London, Richard Martin, Sam Yang</p> <p>Do we need to do a complete regional node dissection for metastatic melanoma nodal disease in 2023? - Andrew Barbour, Brisbane</p> <p>The role of regional surgery for Merkel Cell Carcinoma - Chris Allan, Brisbane</p>	<p>Session 2.3: Basic science 2: immunology Chairs: Karen Sheppard, Melbourne & Nikolas Haass, Brisbane</p> <p>Is location enough? Investigating the role for CD8+ resident memory T cells in metastatic melanoma - Paul Neeson, Melbourne</p> <p>Early detection of melanomas using circulating tumour-specific antibodies - Jessica Da Gama Duarte, Melbourne</p> <p>Expression of Novel Drug Targets in Metastatic Melanoma Patients Treated with Anti-PD-1-Based Therapies - Tuba Nur Gide, Sydney</p> <p>.4 Single-cell sequencing and multicolor immunofluorescence define novel subsets of tumor-infiltrating lymphocytes in uveal melanoma - Jonas Nilsson, Perth</p> <p>Free papers</p>
1500-1530	Afternoon Break		
1530-1700	<p>Session 3.1: Oncology / surgery / dermatology free papers</p>	<p>Session 3.2: Epidemiology / public health free papers</p>	<p>Session 3.3: Basic science 3: melanoma biology Chairs: Elin Gray, Perth & Helen Rizos, Sydney</p> <p>Stable isotope tracing as a tool to study melanoma metabolism - Aparna Rao, Melbourne</p> <p>The female survival advantage in melanoma – are X-linked epigenetic regulators responsible? - Jessamy Tiffen, Sydney</p>

			<p>Cell-to-cell communication in uveal melanoma metastases - Elin Gray, Perth</p> <p>Claudine Bonder, Adelaide</p> <p>Free papers</p>
	<p>Day 1 Closing</p>		

Saturday 25th March 2023

<p>0730-0845</p>	<p>Breakfast Session 2: Optimising care and treatment for BRAF-mut melanoma patients Chair: Georgina Long, Sydney</p> <p>Reinhard Dummer, Zurich (Switzerland)</p> <p>Panel: Andrew Haydon, Melbourne & Megan Lyle</p> <p><i>Sponsored by Pierre Fabre</i></p>	<p>Workshop: Dermoscopy Chair: H. Peter Soyer, Brisbane</p> <p>Harald Kittler, Vienna (Austria) Cliff Rosendahl, Brisbane</p> <p><i>Hosted by AMC</i></p>	<p>Symposium: A Practical Guide to Sentinel Node Biopsy Chair: Mark Smithers, Brisbane</p> <p>Radiology: Kevin London, Sydney Regional surgeon: David Ryan, Lismore Metro surgeon: Alex van Akkooi, Sydney</p> <p>Panel discussions and case presentations <i>Hosted by AMC</i></p>
<p>0900-1030</p>	<p>Session 4.1: Locally advanced disease -multidisciplinary care Chairs: Rachel Roberts-Thomson, Adelaide & Melissa Eastgate, Brisbane</p> <p>The role of adjuvant therapy for stage II melanoma - Rachel Roberts-Thomson, Adelaide</p> <p>The role of adjuvant therapy for stage III melanoma - Andrew Haydon, Melbourne</p> <p>The management of advanced desmoplastic melanoma including neoadjuvant therapy - Megan Lyle, Cairns</p> <p>Management of in-transit melanoma - Alex van Akkooi, Sydney</p> <p>Panel discussion including case presentations</p>	<p>Session 4.2: The interchange between pathologists and clinicians Chairs: Catriona McLean, Melbourne & Duncan Lambie, Brisbane</p> <p>Use and abuse of PRAME and SOX10 in the assessment of a melanocytic lesion - Nathan Harvey, Perth</p> <p>When everything you thought you knew about Spitz goes BAM - Ben Wood, Perth</p> <p>Reconceiving early detection of melanoma: the ACEMID cohort study - Peter Ferguson, Sydney</p> <p>Interventions to improve histopathological agreement may reduce over calling and under calling of melanoma - Matthew Gibson, Sydney</p> <p>The effects of providing dermoscopic images to pathologists interpreting melanocytic lesion - Belinda Lai, Sydney</p> <p>Panel discussion</p>	<p>Session 4.3: Genetic counselling for primary melanoma – workshop (9.00 – 10.45) Chair: Aideen McInerney-Leo</p> <p><i>Restricted to the first 30 participants who will register for a 2-hour workshop. Suitable for primary care / dermatologists and surgeons treating primary disease.</i></p>
<p>1030-1100</p>	<p>Morning Break</p>		
<p>1100-1230</p>	<p>Plenary 2: Neoadjuvant immunotherapy: a gamechanger for melanoma patients Chairs: Victoria Atkinson, Brisbane & Andrew Barbour</p> <p>Perspectives:</p>		

	<p>- The Medical Oncologist - Georgina Long, Sydney - The Pathologist - Richard Scolyer, Sydney - The Surgeon – Alexander van Akkooi, Sydney Discussion panel: Karen van Gorp (consumer) , Alex van Akkooi, Georgina Long, Richard Scolyer</p>		
<p>1230-1345</p>	<p style="text-align: center;">Lunch Break Industry Session: Hot Topics in Melanoma <i>Sponsored by MSD</i></p>		
<p>1345-1515</p>	<p>Session 5.1: Issues in managing advanced melanoma and melanoma at unusual sites Chairs: Victoria Atkinson, Brisbane & Andrew Haydon, Melbourne</p> <p>Has PD/LAG3 systemic therapies reached prime time for advanced disease? - Georgina Long, Sydney</p> <p>Is there ever a role for targeted therapy in advanced melanoma? - Phil Parente, Melbourne</p> <p>Mucosal melanoma/acral melanoma-novel therapies and novel approaches - Matt Carlino, Sydney</p> <p>Uveal melanoma - new and novel therapies - Anthony Joshua, Sydney</p> <p>Case Discussion</p>	<p>Session 5.2: Radiation Oncologist and Melanoma Chairs: Mark Pinkham & Lisa Capelle</p> <p>Role of RT for localized primary cutaneous melanoma and preinvasive disease - Angela Hong, Sydney</p> <p>Role of RT for resected and unresectable stage 3 cutaneous melanoma including ITD - Tim Wang, Sydney</p> <p>Role of SBRT in oligometastatic (oligo-persistent and -progressive) melanoma - Sasha Senth, Melbourne</p> <p>Stereotactic radiosurgery in melanoma - Cecelia DeGzell, Sydney</p> <p>RT + IO interactions to improve melanoma outcomes - Gish Ratnayke, Brisbane</p>	<p>Session 5.3: Overdiagnosis - clinical realities Chairs: Solange Green, Brisbane & Harald Kittler, Vienna (Austria)</p> <p>The rapid rise in cutaneous melanoma diagnosis - Adewole Adamson, Austin (USA)</p> <p>Does overdiagnosis exist in the clinical practice - Erin McMeniman, Brisbane</p> <p>Use of imaging and AI in the context of overdiagnosis - Victoria Mar, Melbourne</p> <p>The role of dermatopathology in overdiagnosis - Duncan Lambie, Brisbane</p> <p>Psychological reactions to in situ melanoma - Monika Janda, Brisbane</p> <p>Overdiagnosis - Which lesions should we leave - Cliff Rosendahl, Brisbane</p> <p>Panel Discussion - Rae Flude (consumer), Adewole Adamson, Erin McMeniman, Victoria Mar, Duncan Lambie, Monika Janda, Cliff Rosendahl</p>
<p>1515-1545</p>	<p style="text-align: center;">Afternoon Break</p>		

<p>1545-1715</p>	<p>Session 6.1: Advanced skin cancer Chairs: Ines da Silva, Sydney & Kiarash Khosrotehrani, Brisbane</p> <p>Merkel cell - the role of adjuvant and neoadjuvant therapies - Wen Xu, Brisbane</p> <p>Translational research in keratinocytic cancers - Kiarash Khosrotehrani, Brisbane</p> <p>The role of surgery for advanced keratinocytic cancers - Sydney Ch'ng, Sydney</p> <p>The role of adjuvant and neoadjuvant therapies for cutaneous SCC - Ines da Silva, Sydney</p> <p>Keratinocytic skin cancers in Transplant and immunosuppressed patients - Miles Andrews, Melbourne</p> <p>Discussion and case presentations with focus on Merkle cell cancer and advanced keratinocytic cancers</p>	<p>Session 6.2: Consumer Session</p>	<p>Session 6.3: Clinico-pathologic Cases Chairs: Duncan Lambie, Brisbane & Catriona McLean, Melbourne</p> <p>Multiple datasets and topics for discussion with panel:</p> <p>GP with skin interest: Cliff Rosendahl, Brisbane & Solange Green, Brisbane</p> <p>Dermatology - Victoria Mar, Melbourne & Jim Muir, Brisbane</p> <p>Pathology - Louise Jackett, Melbourne & Blake O'Brien, Brisbane</p> <p>Surgery: Chris Allan, Brisbane & Sam Yang, Brisbane</p>
	<p>Conference Closing</p>		